MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2016 International Congress

    Pilot study on the long lasting effectivness of an integrated tailored sensory-motor rehabilitation program associated with BoNTA in cervical dystonia

    A. Castagna, M. Ramella, A. Crippa, L. Sciumè, G. Giacobbi, C. Corrini, D. Anastasi, A. Montesano (Milano, Italy)

    Objective: The aim of this study is to assess the long lasting effectiveness of an integrated tailored sensory-motor rehabilitation program (TsmRP) associated with botulinum toxin…
  • 2016 International Congress

    Does GPi-DBS help non motor symptoms in cervical dystonia patients? A retrospective study of 17 patients

    L. Lowry, B. Hammersley, M. Bonello, P. Byrne, N.A. Fletcher, J.O. Farah, P.R. Eldridge, S.H. Alusi (Liverpool, United Kingdom)

    Objective: To study the efficacy of GPi DBS surgery in improving dystonia related severity, disability and pain as well as quality of life in medically…
  • 2016 International Congress

    Structural and connectivity changes after botulinum neurotoxin therapy in blepharospasmus and hemifacial spasm

    C.V. Chirumamilla, G. Deuschl, K.E. Zeuner, M. Muthuraman, S. Groppa (Mainz, Germany)

    Objective: The two primary objectives of this study were to investigate the structural grey matter changes and connectivity differences between patients with BEB and HFS…
  • 2016 International Congress

    Quality of life and epidemiological profile of patients undergoing botulinum toxin treatment

    G. Amorelli, L.F. Vasconcellos, M. Spitz, L.F. Fraga (Rio de Janeiro, Brazil)

    Objective: To trace a clinical and epidemiological profile of patients treated with botulinum toxin, evaluating the impact on quality of life. Background: The Botulinum Toxin…
  • 2016 International Congress

    Assessment of need for treatment with botulinum toxin type A in cervical dystonia patients

    C.L. Vaughan, G.T. Stebbins, C.L. Comella (Charleston, SC, USA)

    Objective: To prospectively assess the interval in weeks between injection of botulinum toxin A (BoNTA) and patient-perceived need for the next injection for treatment of…
  • 2016 International Congress

    Evaluation of stigmatization and quality of life before and after botulinum toxin treatment in hemifacial spasm

    B. Yuksel, F. Genc, A. Yaman, P. Dogan Ak, E. Ozaydin Goksu, A. Aybar, Y. Bicer Gomceli (Antalya, Turkey)

    Objective: Hemifacial spasm (HFS) is a chronic disease that is characterized by involuntary tonic and clonic contractions of the muscles innervated by the ipsilateral facial…
  • 2016 International Congress

    Botulinum neurotoxin type A versus anticholinergics for cervical dystonia in adults – 2016 Cochrane movement disorders group systematic review update

    F.B. Rodrigues, G.S. Duarte, R.E. Marques, M. Castelão, J.J. Ferreira, P. Moore, J. Costa (Lisboa, Portugal)

    Objective: To compare the effects of botulinum toxin A (BtA) versus anticholinergics in adults with cervical dystonia (CD). Background: This is an update of a…
  • 2016 International Congress

    Highlighting the spectrum of practice in the routine management of cervical dystonia with botulinum neurotoxin-A: Baseline injection practice data from MetaCD

    R. Trosch, V.P. Misra, S. Om, P. Maisonobe (Farmington Hills, MI, USA)

    Objective: To describe the spectrum of routine injection practice for botulinum neurotoxin-A (BoNT-A) in the management of cervical dystonia (CD). Background: The success of each…
  • 2016 International Congress

    Botulinum neurotoxin type A versus placebo for hemifacial spasm in adults – 2016 Cochrane movement disorders group systematic review update

    M. Castelão, F.B. Rodrigues, R.E. Marques, G.S. Duarte, J.J. Ferreira, P. Moore, J. Costa (Lisboa, Portugal)

    Objective: To update a Cochrane review comparing botulinum neurotoxin type A (BtA) to placebo in adults with hemifacial spasm (HFS). Background: This is an update…
  • 2016 International Congress

    How satisfied are cervical dystonia patients with their botulinum toxin treatment? Findings from an international observational study

    V.P. Misra, C. Colosimo, D. Charles, T.M. Chung, P. Maisonobe, S. Om (London, United Kingdom)

    Objective: Evaluate patient satisfaction with botulinum neurotoxin-A (BoNT-A) treatment over an injection cycle in routine practice. Background: Benefits of BoNT-A injection in cervical dystonia (CD)…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley